Asian Spectator


The Times

.

Josh Ferris and Justine Guerard Triumph at the 32nd Laguna Phuket Triathlon, Asia’s Longest-Running Triathlon

Australia’s Ferris and France’s Guerard conquer Phuket’s iconic resort racecourse, as international athletes battle for USD 20,000 in prize money.PHUKET, THAILAND – Media OutR...

LONGi to supply 65MW Hi-MO 4 modules to a solar project financ...

TAKASAKI, Japan, March 10, 2020 /PRNewswire-AsiaNet/ -- China solar giant LONGi has signed an order to supply 65MW high performance PV modules to a solar project financed by one of the world...

Sai Life Sciences expands suite of cellular analysis platforms...

CAMBRIDGE, Mass. and HYDERABAD, India, Sept. 11, 2020 /PRNewswire-AsiaNet/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs)...

LONGBRANCH(TM) BOURBON SPARKS CURIOSITY WITH LAUNCH OF NEW CA...

LAWRENCEBURG, Ky., May 11, 2022 /PRNewswire-AsiaNet/ -- The Award-Winning Bourbon Brand Challenges Fans to Question the Conventional with a Zest for Life through Narrative Series of Digital ...

Thailand Prepares to Assume the ASEAN Chairmanship

BANGKOK, Sept. 29, 2018 /PRNewswire-AsiaNet/-- As it prepares to take the ASEAN chairmanship in 2019, Thailand is creating initiatives to increase people-to-people cooperation in the ten mem...

Hong Kong sets out strategies to enhance the appeal and add value to the city’s tourism industry

HONG KONG SAR – Media OutReach Newswire – 21 September 2026 – Enhancing the city's appeal as a destination for tourism and major sports and cultural events was a strong fo...

TCL 8K OD Zero Mini LED TV and Smart Home Appliance Receives C...

HONG KONG, Nov. 11, 2021 /PRNewswire-AsiaNet/ -- TCL Electronics (1070.HK), one of the leading players in the global TV industry and a leading consumer electronics company today announced th...

FIRE Fit To Light Up Oman Fitness Scene

Horizon Fitness announces opening of exciting new boutique fitness concept in Oman MUSCAT, OMAN - Media OutReach - 28 February 2022 - Horizon LLC (Horizon) today announced the addition of F...

On Its 100 Years Anniversary, LUX Aims to Change Feminine Identity With 'In Her Name’

Empowering Women Worldwide Through Inclusive Naming Practices: LUX Launches 'In Her Name' Campaign.SINGAPORE - Media OutReach Newswire - 18 April 2024 - LUX, the global beauty brand under U...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/güvenilir bahis siteleriStreamEastStreamEastjojobet